CuraMab® is a self-developed technological platform that allows the optimization from lab to large scale production of biopharmaceutical proteins, mainly monoclonal antibodies (mAbs) and recombinant proteins from mammalian cell, with a fully humanized post-translational modification (PTM) pattern. With this technological platform, Curaxys is able to produce clinical-grade and commercial amount of mAb as Trastuzumab, among other biosimilars, with the highest yield available so far. (Licensed by CURAXYS).

CuraMab® is a trade mark that belongs to Curaxys

More on Curaxys
We focus on the research, production and commercialization of recombinant proteins added value through the utilization of CuraMab® with specific human cell lines
Our expression system allows us to reach of recombinant protein levels that are clearly above those currently available.
We developed a downstream technological platform on the basis of our own laboratory data.

Latest News

  • Curaxys obtains financing for the purchase of equipment with the help granted by Innplanta 2012
  • Curaxys hires five more technologists.
  • One of the largest biopharmaceutical projects in Europe to be started at Tecnobahía.
  • Innovaxis, a novel company for “custom medicine”
  • Strategic Alliance for cancer disease
  • UCA and Curaxys create a Cathedra in biopharmaceuticals in order to research biosimilar proteins
  • Curaxys is ranked among the world top ten companies in the research of biologic generic medicines

  • Copyright 2012 Curaxys. All Rights Reserved
    Legal Advice